SynthesisBMC cancer2025
Diagnostic and prognostic values of tsRNAs in lung cancer: a meta-analysis.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Targeting the hsa-miR-155-5p-BACH1-MMP-9 Signaling Hub in Lung Cancer: A Novel Anticancer Mechanism of Thymoquinone.Biomolecules · 2026Article
- Transfer RNA expression, modification, and derived small RNAs in cancer biology and clinical potential.Frontiers in immunology · 2026Review
- Plasma Small Extracellular Vesicle microRNAs as Non-Invasive Biomarkers for Lung Cancer Detection.International journal of nanomedicine · 2025Article
- Mitochondrial non-coding RNAs as novel biomarkers and therapeutic targets in lung cancer integration of traditional bioinformatics and machine learning approaches.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLung cancer (LC) is the leading cause of cancer-related death in humans. tRNA-derived small RNA (tsRNA) is a novel biomarker that plays a crucial role in the genesis and development of LC. In this study, we aimed to investigate the value of differentially expressed tsRNAs in LC through meta-analysis.
methodsPubMed and Web of Science were searched for articles published up to January 10, 2024. Diagnostic odds ratios (DORs) and areas under the receiver operating characteristic curve (AUCs) were used to evaluate the potential of tsRNAs as diagnostic markers for LC. Furthermore, hazard ratios (HRs) and 95% confidence intervals (95% CIs) were used to analyze association of tsRNAs with LC prognosis.
resultsIn total, 12 studies were included in the analysis. Our results indicated that the combined DOR of total tsRNAs for LC diagnosis was 7.32; the AUC was 0.81. Subgroup analysis revealed that high levels of tsRNAs in serum had good diagnostic efficacy (DOR = 16.56, AUC = 0.88). Moreover, a high tsRNAs level was associated with a worse prognosis in LC patients (HR = 1.59, 95% CI: 1.33-1.90).
conclusionOur findings suggest that a high tsRNAs level has potential value for diagnosis and prognosis of LC patients. However, further high-quality studies are needed to validate our results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.